There is always hope beyond what you take it for granted.
We're dedicated to improve womens health through science.
What We Do
Ovarian Cancer
Breast and pancreatic cancer
Breast and pancreatic cancer
High grade serous epithelial ovarian cancer (HGSOC) is the leading cause of death from gynecologic malignancies and the fifth most common cause of cancer-related death in women in the United States. One in three females are affected by poor ovarian health, there is an unmet need, specifically for those diagnosed with ovarian cancer. Akk
High grade serous epithelial ovarian cancer (HGSOC) is the leading cause of death from gynecologic malignancies and the fifth most common cause of cancer-related death in women in the United States. One in three females are affected by poor ovarian health, there is an unmet need, specifically for those diagnosed with ovarian cancer. Akkadian Therapeutics lead p53 mutant reactivator, AKT-100 has demonstrated robust activity as a single agent and in combination with PARP inhibitors in multiple preclinical assays. Presently in its early drug discovery stage.
Breast and pancreatic cancer
Breast and pancreatic cancer
Breast and pancreatic cancer
Breast cancer is the most commonly diagnosed cancer among US women. Recent study confirms that pancreatic cancer rates rising faster in women than men. Our team is constantly keeping up with research and technology and strive to find better ways to improve the health of women in an ever-changing industry. Akkadians novel molecules, AKT-1
Breast cancer is the most commonly diagnosed cancer among US women. Recent study confirms that pancreatic cancer rates rising faster in women than men. Our team is constantly keeping up with research and technology and strive to find better ways to improve the health of women in an ever-changing industry. Akkadians novel molecules, AKT-100 and AKT-106 have demonstrated robust activity in multiple preclinical assays in breast cancer as well as pancreatic cancer cell lines. AKT-100 and AKT-106 are presently in their early drug discovery stage.
Preeclampsia
Breast and pancreatic cancer
Preeclampsia
Preeclampsia (PE) is a serious complication affecting 5-7% of pregnancies worldwide. It is
characterized by high maternal blood pressure, kidney dysfunction, proteinuria, and in severe
cases, eclampsia. No therapy to treat the underlying causes is currently available. The most
effective recourse is delivery of the baby, nearly always prem
Preeclampsia (PE) is a serious complication affecting 5-7% of pregnancies worldwide. It is
characterized by high maternal blood pressure, kidney dysfunction, proteinuria, and in severe
cases, eclampsia. No therapy to treat the underlying causes is currently available. The most
effective recourse is delivery of the baby, nearly always prematurely, with reduced newborn
survival and risk of long-lasting developmental impairment. Akkadian Therapeutics is
developing AKT-1005 for PE therapy. AKT-1005 exhibited major benefits in and in vitro and in
an established rodent model of PE. These include a reversal of maternal hypertension, a
reduction in markers of oxidant stress as well as prevention of kidney dysfunction. AKT-1005
presently is in its early drug discovery stage.
Our Team
AKTX team members and consultants are renowned international scholars and a seasoned pharmaceutical drug development professionals, clinician-scientist, synthetic process chemist, analytical and formulation chemist, pharmacologist, toxicologist, metabolism specialist, pathologist, statistician and molecular and cell biologist, with a history of many hundreds of publications in top-tier journals (Nature, J Exp Med, J Med Chem, Biology, Circulation, Gastroenterology, J Clinical Investigation, PNAS, etc.). The Company’s staff in aggregate has received multiple NIH grants, including numerous R01’s and U01’s.
Founders of AKTX have accomplished scientists, and have invented a series of oncology, CNS and ocular drugs. We are internationally-recognized expert on critical illness, author of 175 peer-reviewed publications on free radical stress, reperfusion injury, and circulatory shock, and former executives and directors at Pharmaceutical companies for 25 years where we led medicinal chemistry, basic research, pharmacology, quality assurance, regulatory affairs, GMP manufacturing, and clinical investigation.
Programs and Pipeline
Each of our drug discovery programs follows the principles of our R&D guidelines: Selection of targets that are genetically linked to the disease, modification of our molecules based on delivery route, and guiding clinical development through the use of critical clinical biomarkers.